TUMOR DEVELOPMENT

肿瘤发展

基本信息

批准号：
8473818
负责人：
ROBERT GLEN OSHIMA
金额：
$ 18.36万
依托单位：
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/8473818
关键词：
Area Bexarotene Biology Cancer Center Cancer Center Support Grant Cell Cycle Regulation Cells Collaborations Colon Cutaneous Defect Development Developmental Process Diagnostic Neoplasm Staging Epigenetic Process FDA approved Faculty Funding Genetic Genetic Processes Grant Interest Group Joints Laboratories Lead Malignant Neoplasms Mammary gland Mentors Microsatellite Instability Modeling Mus Mutation Nuclear Receptors Pathway interactions Peer Review Pharmaceutical Chemistry Pharmaceutical Preparations Phenotype Population Postdoctoral Fellow Productivity Program Development Publications RNA Research Resources Retinoids Role Signal Transduction Stem cells T-Cell Lymphoma Tissues Tretinoin Tumor stage United States National Institutes of Health cancer genetics cancer therapy carcinogenesis chromatin modification cost graduate student meetings member mouse model multidisciplinary neoplastic cell notch protein novel programs stem cell biology tumor

项目摘要

The Tumor Development Program focuses on understanding the genetic, epigenetic and developmental processes that take place in tumor-initiating cells and tumor-susceptible tissues during tumor development. The Program was established in 2007 by combining the Oncodevelopmental Biology Program with the Cancer Genetics & Epigenetics Program. This merger logically combines expertise in developmental aspects of cancer with genetic and epigenetic mechanisms underiying cancer development. Drs. Robert Oshima and Manuel Perucho are co-Leaders of the Program, which consists of 14 full members and 2 adjunct members. The Program comprises three overarching themes, which benefit from highly interdisciplinary program membership, including expertise in genetic and epigenetic pathways, stem cell biology, mouse models of cancer and medicinal chemistry: 1- Genetic and epigenetic changes in cancer. Program members continue to lead the field of the "mutator phenotype" and carcinogenesis, with additional strengths in the areas of chromatin modifications, cell cycle regulation and checkpoint signaling, and RNA biology; 2- Stem cell biology, with focus of Notch and Wnt signaling, and mouse models of cancer, with focus on mammary gland and colon models. The Program is a resource for all CCSG Programs due to its expertise in mouse tumor models; and 3- Novel targets in cancer treatment, with focus on nuclear receptors and retinoic acids. Notably, members of the Program have developed a retinoid-like drug, Targretin¿, which is FDA-approved for the treatment cutaneous T cell lymphoma. Members of this collaborative and multidisciplinary Program interact at a number of levels, including monthly faculty meetings and through collaborative grants. Program funding is currently at $12.9MM in annual total costs ($7.0MM direct). Program members participate in two POIs (1 from NCI), three U54/U19 grants, and 15 additional collaborative peer-reviewed federal and state grants. Program members also have 17 NIH ROIs (7 from NCI). The Program's productivity is further reflected by 345 publications since last review, and by 58 Program publications in 2008, which represent 14% of intra- and 21% of inter-programmatic collaborations, respectively.

肿瘤发展项目侧重于了解遗传、表观遗传和发育肿瘤发展过程中肿瘤起始细胞和肿瘤易感组织中发生的过程。该项目成立于 2007 年，将肿瘤发育生物学项目与癌症遗传学和表观遗传学项目逻辑上结合了发育方面的专业知识。癌症发展的遗传和表观遗传机制的各个方面。 Oshima 和 Manuel Perucho 是该计划的共同领导者，该计划由 14 名正式成员和 2 名成员组成。该计划包括三个总体主题，受益匪浅。跨学科计划成员资格，包括遗传和表观遗传途径、干细胞方面的专业知识生物学、癌症小鼠模型和药物化学：1- 癌症的遗传和表观遗传变化。计划成员继续引领“突变表型”和致癌作用领域，并有更多研究成果在染色质修饰、细胞周期调控和检查点信号传导以及 RNA 领域具有优势生物学；2- 干细胞生物学，重点是 Notch 和 Wnt 信号传导，以及小鼠癌症模型，重点是该计划是所有 CCSG 计划的资源。小鼠肿瘤模型方面的专业知识；以及 3- 癌症治疗的新靶点，重点是核受体值得注意的是，该计划的成员开发了一种类视黄醇药物，Targretin¿ ，哪个经 FDA 批准用于治疗皮肤 T 细胞淋巴瘤。这个协作和多学科计划的成员在多个层面上进行互动，包括每月教师会议和合作资助目前每年总计 12.9MM 美元。费用（直接 7.0MM 美元）。计划成员参与两项 POI（1 个来自 NCI）、三项 U54/U19 补助金，以及另外 15 名合作同行评审的联邦和州资助项目成员还获得 17 名 NIH 资助。自上次审查以来，345 篇出版物进一步反映了 ROI（NCI 的 7 个）。 2008 年有 58 份计划出版物，占计划内出版物的 14%，计划间出版物的 21% 分别进行合作。